Prothex is a clinical-stage pharma company
Working to help patients receiving radiation therapy
We hope that we can improve patient experiences with cancer treatment and improve outcomes at the same time.
For decades, radiation therapy has been widely and effectively used in the treatment of many cancers. Unfortunately, the very aspect that makes radiation therapy so effective against cancer also has tremendous potential to damage the healthy, normal tissues near the cancerous tumors. The side effects of radiation therapy can cause agony for patients, and often limit the radiation dosage that doctors can deliver to patients.
Although RRx-001 has not been approved to date for any indication, we believe that it has the potential to limit the ravages of radiation on normal tissues, and potentially provide benefit to patients during and after radiation therapy for their cancer.
Our team of seasoned pharmaceutical developers is currently exploring that potential in clinical trials and readying RRx-001 for review by global health authorities prior to commercialization.
Prothex is open to new partnerships that help us fulfill our mission.Connect With Us
A novel compound being developed by Prothex, currently in a Phase 2a trial
The Prothex team consists of experienced drug development professionals who are motivated to identify and prove the value of new therapies for cancer patients. In the laboratory and in the clinic, we’ve dedicated all of our energies to move medicine forward and improve lives.